Mode
Text Size
Log in / Sign up
Phase 3 N=68 Treatment

Bone Properties in Hypoparathyroidism: Effects of PTH

Hypoparathyroidism

Enrolled (actual)
68
Serious AEs
22.1%
Results posted
Jul 2015
Primary outcome: Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
PTH (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
John P. Bilezikian
Primary completion
Jan 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Requirements for Calcium Supplementation
3.03; 1.66
SECONDARY
Percent Change in BMD From Baseline to 24 Months by DXA
2.9; 0.95; -2.4
SECONDARY
Trabecular Width
144; 128
SECONDARY
Trabecular Number
1.74; 2.07
SECONDARY
Cortical Porosity
7.4; 9.2
SECONDARY
Mineralizing Surface
0.7; 7.1

Summary

Whereas much information is known about the properties of bone in primary hyperparathyroidism, a disorder of parathyroid hormone (PTH) excess, virtually nothing is known about the skeleton in hypoparathyroidism, a disorder in which PTH is absent. The purpose of this research project is to test the hypothesis that the skeleton in hypoparathyroidism is abnormal in its metabolic, densitometric, geometric, biomechanical and microarchitectural features. We will also test the hypothesis that the skeleton is dependent upon PTH for normal structure and function. Using non-invasive approaches as well as direct analysis of bone itself, the human hypoparathyroid skeleton will be thoroughly characterized. With each patient serving as his/her own control, we will determine how, to what extent, and in what ways the administration of PTH restores skeletal dynamics and structure to the hypoparathyroid skeleton. In this way, we will identify those structural and dynamic elements of the skeleton that are influenced by or dependent upon PTH. Methods to be utilized include dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography, geometry and size quantification, histomorphometry by standard and microCT methods, finite element analysis, biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform Infrared Spectroscopy. This research project will extend our knowledge of the skeletal effects of PTH to its deficient range and thus complete our understanding of PTH action on bone gained by our many years of studying PTH overexpression in primary hyperparathyroidism. This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis.

Eligibility Criteria

Inclusion Criteria

  • Hypoparathyroidism

Exclusion Criteria

  • Bisphosphonate use
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00473265). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search